VERDESO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERDESO (VERDESO).
Clobetasol propionate is a highly potent corticosteroid that binds to glucocorticoid receptors, inducing the synthesis of lipocortins which inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Hepatic metabolism via CYP3A4-mediated pathways |
| Excretion | Primarily biliary/fecal excretion (approximately 90%) as unchanged drug and metabolites; renal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 100 hours (range 70-140 hours), supporting once-weekly topical application. |
| Protein binding | >99% bound to plasma proteins, predominantly to albumin and lipoproteins. |
| Volume of Distribution | Very large (>100 L/kg) after systemic absorption, indicating extensive distribution into tissues, including skin and adipose. |
| Bioavailability | Topical: Approximately 1-2% systemically absorbed through intact skin; higher with occlusive dressings or diseased skin. |
| Onset of Action | Topical: Clinical improvement in plaque psoriasis typically observed within 2-4 weeks of once-daily application. |
| Duration of Action | After discontinuation, therapeutic effect may persist for several weeks; however, reapplication is needed weekly to maintain response. |
Topical: apply a thin layer of VERDESO (clobetasol propionate) foam, 0.05%, to affected areas twice daily (morning and night) for up to 2 weeks; maximum weekly dose should not exceed 50 g.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for renal impairment; systemic absorption is minimal with topical use. |
| Liver impairment | No specific dose adjustment recommendations for hepatic impairment; use with caution due to potential increased systemic absorption if extensive areas are treated. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established; for children 12 years and older, same as adult dosing (apply twice daily for up to 2 weeks). Use the smallest amount needed. |
| Geriatric use | No specific dose adjustment required; use caution due to thinner skin and potential for increased systemic absorption; limit treatment to smallest amount and shortest duration necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VERDESO (VERDESO).
| Breastfeeding | It is unknown whether topically applied clobetasol propionate is excreted in human milk. However, systemically administered corticosteroids appear in human milk and could suppress growth or interfere with endogenous corticosteroid production. The M/P ratio for clobetasol propionate is not established. Caution should be exercised when VERDESO is administered to a nursing woman. Avoid application to the breast area to prevent infant ingestion. Use the lowest potency and smallest amount necessary. |
| Teratogenic Risk | VERDESO (clobetasol propionate) is a super-high potency topical corticosteroid. Systemic absorption is minimal with topical use but may be increased with application to large surface areas, under occlusion, or on broken skin. In pregnancy, no adequate and well-controlled studies exist. Based on animal studies and the known effects of corticosteroids, use during pregnancy should be avoided unless the potential benefit justifies the risk to the fetus. First trimester: There is a potential for increased risk of orofacial clefts (based on systemic corticosteroids), but data for topical use are insufficient. Second/third trimester: Chronic exposure may lead to fetal growth restriction and hypothalamic-pituitary-adrenal axis suppression. Use only if clearly needed and limit to small areas, avoid occlusion, and use for short duration. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to clobetasol propionate or any component of the formulation"]
| Precautions | ["Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Cushing's syndrome","hyperglycemia","glucosuria","Local adverse reactions including skin atrophy, striae, telangiectasias, and secondary infections","Avoid use on face, axillae, or groin","Use with caution in pediatric patients due to increased skin surface-to-body weight ratio"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of maternal hypothalamic-pituitary-adrenal axis suppression (e.g., fatigue, hypotension, hypoglycemia) if large areas are treated or occlusion is used. Monitor fetal growth via ultrasound if used chronically during pregnancy. In the neonate, monitor for adrenal suppression (e.g., poor feeding, vomiting, lethargy) if maternal use was prolonged or high-dose. |
| Fertility Effects | Animal studies with clobetasol propionate at doses exceeding the maximum human topical application have shown no impairment of fertility. No human data are available on the effects of topical corticosteroids on fertility. It is unlikely that topical use at recommended doses impairs fertility, but systemic absorption from extensive use could theoretically affect reproductive function. |